A double-blind comparison of desipramine and placebo in children and adolescents with chronic tic disorder and comorbid attention-deficit/hyperactivity disorder

Archives of General Psychiatry

Volumn 59, Issue 7, 2002, Pages 649-656

  Spencer, Thomas ^a,b   Biederman, Joseph ^a,b   Coffey, Barbara ^b,c   Geller, Daniel ^b,c   Crawford, Margaret ^a   Bearman, Sarah Kate ^a   Tarazi, Reem ^a   Faraone, Stephen V ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MCLEAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DESIPRAMINE; PLACEBO; TRICYCLIC ANTIDEPRESSANT AGENT;

ADOLESCENT; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; COGNITION; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FAMILY HISTORY; FEMALE; GILLES DE LA TOURETTE SYNDROME; HEADACHE; HUMAN; MALE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SLEEP DISORDER; SOCIOECONOMICS; TITRIMETRY; TREATMENT OUTCOME;

EID: 0036304326     PISSN: 0003990X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archpsyc.59.7.649     Document Type: Article

References (41)

1. Tourette disorder and ADHD
2. A case of Tourette's syndrome with symptoms of attention deficit disorder treated with desipramine
3. Desipramine treatment of boys with attention-deficit hyperactivity disorder and tics: Preliminary clinical experience
4. Desipramine in the treatment of children with tic disorder or Tourette's syndrome and attention deficit hyperactivity disorder
5. The treatment of attention-deficit hyperactivity disorder in Tourette's syndrome: A double-blind placebo-controlled study with clonidine and desipramine
6. Methods in genetic epidemiology
7. Detection of interference by cyclobenzaprine in liquid chromatographic assays of tricyclic antidepressants
8. Critical measurement issues in learning disabilities
9. Intellectual performance and school failure in children with attention deficit hyperactivity disorder and in their siblings
10. A double blind, crossover comparison of methylphenidate and placebo in adults with childhood onset attention deficit hyperactivity disorder
11. Parent and teacher ratings of ADHD symptoms: Psychometric properties in a community-based sample
12. The Yale Global Tic Severity Scale: Initial testing of a clinician-rated scale of tic severity
13. Children's Yale-Brown Obsessive Compulsive Scale: Reliability and validity
14. CDI (the Children's Depression Inventory)
15. Ratings for anxiety disorders
16. The global assessment scale: A procedure for measuring overall severity of psychiatric disturbance
17. Longitudinal data analysis using generalized linear models
18. Models for longitudinal data: A generalized estimating equation approach
19. Controlled study of haloperidol, pimozide and placebo for the treatment of Gilles de la Tourette's syndrome
20. Ziprasidone treatment of children and adolescents with Tourette's syndrome: A pilot study
21. A placebo-controlled study of guanfacine ofguanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder
22. Clonidine treatment of Gilles de la Tourette's syndrome
23. Pharmacotherapy of attention deficit hyperactivity disorder across the lifecycle: A literature review
24. A double-blind placebo controlled study of desipramine in the treatment of attention deficit disorder, I: Efficacy
25. Attention-deficit/hyperactivy disorder (ADHD) as a noradrenergic disorder
26. A double-blind placebo controlled study of desipramine in the treatment of attention deftcit disorder, II: Serum drug levels and cardiovascular findings
27. Sudden death in children treated with a tricyclic antidepressant
28. Case study: Two additional sudden deaths with tricyclic antidepressants
29. Sudden death putatively related to desipramine treatment in youth: A fifth case and a review of speculative mechanisms
30. Estimation of the association between desipramine and the risk for sudden death in 5- to 14-year-old children
31. AHA scientific statement: Cardiovascular monitoring of children and adolescents receiving psychotropic drugs
32. Anxiety and depressive disorders in attention deficit disorder with hyperactivity: New findings
33. A prospective 4-year follow-up study of attention-deficit hyperactivity and related disorders
34. Comorbidity
35. Diagnoses of attention-deficit hyperactivity disorder from parent reports predict diagnoses based on teacher reports